Lung cancer represents the major cause of cancer-related deaths among men and ranks as the second leading cause of cancer among women worldwide.
Therefore, favourable biomarkers are of great importance in the prediction of early metastasis of patients with lung cancer.
MicroRNAs (miRNAs), a group of small non-coding RNAs, contribute to regulate gene expression at the posttranscriptional level through perfect or partial base-pairing, mainly at the 3′UTR of the target messenger RNA. MiR-326, for instance, was first identified among a set of miRNAs with remarkable high expression in neurons. 8 It has been implicated that abnormal miR-326 expression participates in a variety of pathological process, including multiple sclerosis, endometrial cancer, gastric cancer, lung cancer, osteosarcoma, pulmonary fibrosis and breast tumours. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Of note, recent evidence revealed that miR-326 regulated HbF synthesis by targeting erythroid Krüppel-like factor (KLF), indicating the targeting effect of miR-326 on KLF. 9 Alternatively, miR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein 1 (Sp1). 12 Krüppel-like factor 3 (KLF3/BKLF), a member of the KLF family, was initially cloned from erythroid cells in a screen for factors with homology to the DNA-binding domain of EKLF. 22, 23 KLF3 encodes a sequence-specific transcriptional repressor with three highly conserved C-terminal C2H2 zinc finger motifs that bind CACCC boxes and other GC-rich elements in the promoter and enhancer of target genes. 23, 24 The N-terminal domains are less conserved, and individual KLFs integrate different regulators to function as transcriptional activators or repressors. 25 For example, recruitment of the acetyltransferases p300/CBP by KLF1 potentiates its activation of the β-globin gene. 26 However, KLF3 functions as a transcriptional repressor via recruitment of C-terminal binding proteins 1 and 2 (CtBP1/2), 27 ,28 which in turn facilitates assembly of a potent silencing complex that drives epigenetic modification of gene regulatory regions. 25, [27] [28] [29] Moreover, KLF3 is widely expressed and involved in multiple processes, such as erythropoiesis, metabolism and B lymphopoiesis. 25, [30] [31] [32] [33] [34] [35] Although the roles of KLF3 have been broadly investigated in developmental processes, little is known about the function of KLF3 in lung cancer progression.
Specificity protein 1 (Sp1) is a transcription factor that is ubiquitously expressed in many mammalian cell types. 36 Clinical evidences
showed that Sp1 was overexpressed in a number of human cancers, such as gastric cancer, 37 pancreatic adenocarcinoma 38 and hepatocellular carcinoma. 39 Emerging evidences showed that Sp1 accelerates tumour growth and metastasis through regulating gene transcription. 40, 41 For example, overexpression of Sp1 increased the invasiveness of glioma cells via upregulating the expression and activity of MMP-2.
42
Choi et al also reported that Sp1 could bind to the promoter region of Slug and repressed EMT process. 43 However, given many potential physiologic roles of Sp1, the target genes of Sp1 remain to be clearly characterized. Whether Sp1 could affect the expression of KLF3 in lung cancer has never been reported. Our preview studies have revealed F I G U R E 1 KLF3 is overexpressed in lung cancer tissues and cell lines. A, The mRNA level of KLF3 was measured by real-time PCR. The results showed that KLF3 was upregulated in lung cancer tissues compared with paired adjacent normal tissues (N = 40), P < 0.001. B, Western blot analysis revealed that KLF3 was upregulated in lung cancer tissues. C and D, The mRNA and protein level of KLF3 was measured by real-time PCR and Western blot in the human bronchial epithelial cell line HBEC and various lung cancer cell lines (A549, 95D, NCI-H460, HLAmp and H838). E, Immunohistochemical analysis indicated that KLF3 was highly expressed in lung cancer tissues compared to that in normal tissues (×400). *indicates that P < 0.05 vs HBECs. **indicates that P < 0.001 vs HBECs that miR-326 overexpression inhibited cell proliferation and migration in lung cancer. 44 The potential targets, KLF and Sp1, were previously reported involved in the growth of lung cancer cells. [45] [46] [47] In this study, we aim to explore the possibility as well as related mechanisms of miR-326-Sp1-KLF3 axis in the regulation of lung cancer development.
| MATERIAL S AND ME THODS
For detailed Materials and methods, please see Supporting
Information. For related sequences in the experiment please see Tables 1-3 .
| RE SULTS

| KLF3 is overexpressed in human lung cancer tissues
To explore the potential role of KLF3 in lung cancer progression, we firstly assessed the expression level of KLF3 in lung cancer tissues.
Forty lung cancer tissues and paired tumour-adjacent normal tissues
were collected from Jiangsu Province Hospital, and the mRNA level of KLF3 was examined by real-time PCR. The results showed that KLF3 was overexpressed in lung cancer tissues compared with that in adjacent normal tissues ( Figure 1A , P < 0.001). Furthermore, we performed Western blot to evaluate the protein level of KLF3 in lung cancer tissues. Similarly, the KLF3 expression was highly upregulated in lung cancer tissues compared to that in the adjacent normal control ( Figure 1B ). The result of IHC indicated that the amount of KLF3 protein in lung cancer tissues was remarkably increased compared to that in normal lung tissues ( Figure 1E ). Then, we examined the expression of KLF3 in different lung cancer cell lines by real-time PCR and Western blot. As shown in Figure 1C and D, the mRNA and protein levels of KLF3 were also significantly higher in lung cancer cell lines than that in control HBECs, especially in A549 and 95D cells (P < 0.01). Together, these results suggested that the highly expressed KLF3 may be associated with lung cancer progression.
| Effects of suppression of KLF3 on lung cancer cells
To better understand the functional significance of KLF3 in regu- Together, these results suggest that KLF3 facilitates the proliferation of lung cancer cells and may function as an oncogene during lung cancer progression.
| Downregulation of KLF3 inhibited cell migration and invasion
A critical feature of lung cancer is aggressive behaviour in distant metastasis sites including lymph node. Cell migration and invasion are important steps in the process of metastasis. To determine whether KLF3 affects inhuman lung cancer cell migration and invasion, wound healing and cell invasion assays were performed.
The results showed that in untreated A549 cells, wound closure occurred gradually at 48 hours after scratch, whereas this effect was significantly reduced by the treatment of si-KLF3 ( Figure 3A ). 
Similar results were obtained in 95D cells (Figure 3B
)
| The block of KLF3 suppressed the activation of JAK2/STAT3 and PI3K/AKT signalling pathways in vitro
Considering that the promoting effect of KLF3 on cell growth and migration, we performed Western blot assay to measure which signalling pathways were involved by KLF3. As revealed in Figure 4 , the phosphorylation levels of JAK2, STAT3, PI3K and AKT were downregulated in the absence of KLF3 in both A549
and 95D cells in vitro, suggesting that JAK2/STAT3 and PI3K/AKT signalling pathways may be involved in lung cancer progression regulated by KLF3.
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| Sp1 is positively correlated with the expression of KLF3
Based on the above findings, the function of KLF3 in promoting cell proliferation, migration and invasion have been well demonstrated.
However, little is known about the regulatory mechanism of KLF3 in lung cancer cells. Through bioinformatics analysis of the proximal promoter of KLF3, we found that there are some putative binding sites of Sp1 ( Figure S1 ). Therefore, we performed experiments to investigate the possible relation between KLF3 and Sp1. Firstly, we detected the expression of Sp1 in lung cancer tissues through real-time PCR and Western blot. The results showed that Sp1 was upregulated in lung cancer tissues compared with that in the adjacent normal tissues ( Figure 5A and B, P < 0.001), which correlated with the expression of KLF3 in lung cancer tissues ( Figure 1A and B). The IHC data also indicated that the level of Sp1 in lung cancer tissues was evidently elevated compared to that in normal lung tissues ( Figure 5C ). As expected, the mRNA and protein levels of Sp1
were also elevated in different lung cancer cell lines compared with that in the HBECs ( Figure 5D and E). Next, we examined the expression of KLF3 after reducing of Sp1 level in A549 and 95D cells. Figure 5F showed that the mRNA level of KLF3 was downregulated with that in the NC group (P < 0.01). Similarly, the mRNA expression of KLF3 was also decreased in 95D cells ( Figure 5G , P < 0.01).
Moreover, Western blot analysis revealed that the protein level of KLF3 was obviously decreased after expression of Sp1 declined in A549 and 95D cells ( Figure 5H ). These data indicated Sp1 positively correlated with the expression of KLF3 in lung cancer cells.
| KLF3 is a direct target of Sp1
To further explore the molecular basis for this regulation, we amplified the promoter region of KLF3 and performed dual-luciferase reporter assay. The wild-type (WT) and mutant promoters were To further determine whether KLF3 is a direct target gene of Sp1, we performed electrophoretic mobility shift assays (EMSAs) in vitro using the nuclear extracts from A549 cells and the oligonucleotide probes containing the predicted Sp1 binding sites. The results demonstrated that shift bands were observed when probes were incubated with nuclear extracts ( Figure 6B ). Moreover, as expected, super-shift bands were observed when Sp1 antibody was added to the binding system ( Figure 6B ). In addition, chromatin immunoprecipitation (ChIP) assay was initially employed to further determine whether Sp1 could bind to the promoter of KLF3. The pull-down DNA was identified by RT-PCR and the results showed that KLF3 was markedly amplified from the Sp1-immunoprecipitated A549
chromatins, but absent from chromatins immunoprecipitated by IgG ( Figure 6C ). In summary, these results demonstrate that KLF3 is a direct target gene of Sp1.
| Sp1 is a downstream target of miR-326
In our preview studies, we have found that miR-326 inhibited lung cancer cell proliferation and migration. 44 Meanwhile, through bioinformatics analysis such as JASPAR and TargetScan, we found the 3′UTR regions of KLF3 and Sp1 contained the putative binding sites of miR-326, suggesting Sp1 and KLF3 may be potential downstream targets of miR-326. To verify the prediction, we firstly examined the level of miR-326 in lung cancer tissues and cell lines.
As shown in Figure 7A , compared with the normal tissues, miR-326
was significantly downregulated in lung cancer tissues. We fur- Through analysis of a dataset of lung cancer that includes 40 patients, we found that decreased miR-326 expression was associated with poor prognosis among patients with lung cancer ( Figure 8A , P = 0.003). Of note, the patients with high level of KLF3 were associated with poor overall survival (OS) caused by lung cancer F I G U R E 5 KLF3 expression is positively regulated by Sp1. A, The mRNA level of Sp1 was detected by real-time PCR. Compared with the normal tissues, Sp1 was upregulated in lung cancer tissues, P < 0.001. B, Western blot analysis revealed that Sp1 was upregulated in lung cancer tissues. C, Immunohistochemical analysis indicated that the level of Sp1 was increased in lung cancer tissues compared to that in normal tissues (×400). D and E, The mRNA and protein levels of Sp1 were examined by real-time PCR and Western blot. The results showed that Sp1 was overexpressed in lung cancer cell lines. ** indicates that P < 0.001 vs HBECs. F and G, Real-time PCR results showed that KLF3 expression was downregulated after silencing the expression of Sp1 in A549 and 95D cells. Mean ± SD. **indicates that P < 0.01; # indicates that P < 0.001. H, Western blot analysis confirmed that knockdown the expression of Sp1 significantly reduced KLF3 expression F I G U R E 6 KLF3 is a direct target gene of Sp1. A, The luciferase activity of KLF3 was detected by Dual-luciferase report assay after transfection of the WT and Mutant constructs alone or together with the Sp1 expression vector. The results showed that KLF3 promoter activity was significantly enhanced by Sp1. #indicates that P < 0.001. B, EMSAs were used to investigate the binding of Sp1 and KLF3 promoter in vitro. Nuclear protein was extracted from A549 cells. When DNA probes were incubated with nuclear extracts, a specific DNAprotein complex was observed and was supershifted by the anti-Sp1 antibody. C, ChIP analysis of Sp1 at the KLF3 promoter region in A549 cells. The results suggested that Sp1 can directly bind to the promoter region of KLF3 F I G U R E 7 Sp1 is a direct downstream target of miR-326. A, Relative expression of miR-326 in lung cancer tissues was confirmed by real-time PCR. N = 40. P < 0.001. B, Correlation analysis between miR-326 and Sp1 levels. P < 0.01. C, Correlation analysis between Sp1 and KLF3 expressions. P < 0.001. D, Real-time PCR results revealed that miR-326 was downregulated in lung cancer cell lines. **P < 0.001 vs HBECs. E, Overexpression of miR-326 downregulated the expression of Sp1 and KLF3 in A549 cells. Mean ± SD. *P < 0.05; #P < 0.05. F, Overexpression of miR-326 reduced the expression of Sp1 and KLF3 in 95D cells. Mean ± SD. *P < 0.05; #P < 0.05. G, Western blot analysis demonstrated that miR-326 inhibited Sp1 and KLF3 expression in A549 and 95D cells. H, Luciferase activity of Sp1 wild type (wt) was inhibited by using miR-326 mimics, compared to Sp1 mutant (mut). #P < 0.05. I, No significant difference of luciferase activity of KLF3 wild type (wt) and KLF3 mutant (mut) was found by using miR-326 mimics. #P > 0.05. J, The levels of Sp1 and KLF3 mRNAs were significantly reduced in group of miR-326 inhibitor+siSP1 than those of miR-326 inhibitor+siRNA-NC in both A549 and 95D cells. miR-326 antagomir was used as inhibitor. *P < 0.05; #P < 0.05; **P < 0.01; ##P < 0.01. K, The expressions of Sp1 and KLF3 proteins were obviously decreased in group of miR-326 inhibitor+siSP1 than those of miR-326 inhibitor+siRNA-NC in both A549 and 95D cells. miR-326 antagomir was used as inhibitor ( Figure 8B , P = 0.001). Clinicopathologic features were compared between these groups (Table 4) , and significantly higher recurrence as well as death rate was observed in lung cancer patients with low miR-326 and high KLF3 levels, when compared to the high-miR-326 group and the low-KLF3 group (P < 0.05). However, the miR-326
and KLF3 expression levels were not associated with age (P = 0.093
and P = 0.069, respectively), gender (P = 0.05) and TNM tumour stage (P = 0.278 and P = 0.207, respectively). These findings indicate that miR-326/Sp1/KLF3 regulatory axis participated in lung cancer progression.
| The decrease of KLF3 inhibited the growth of xenograft tumour in nude mice
To further investigate the effect of KLF3 on tumour growth in vivo, 
| D ISCUSS I ON
KLF3 was originally discovered as a CACCC box-binding transcription factor in erythroid cells. 48 In fact, similar to other KLF members, KLF3 exhibits both transcriptional activation and repression via interaction with other factors. 27, 49 Although the role of KLF3 has been extensively studied in the development of hematopoietic system, little is known about KLF3 in cancer. In 2011, Magali et al reported that the expression of KLF3 was downregulated in patients with acute myeloid leukaemia compared with healthy donors. 50 In addition, Sachdeva et al found that KLF3 expression was downregulated in both primary mouse and human metastatic sarcomas due to the promoter hypermethylation. 51 Intriguingly, increased Krüppel-like factor 6 splice variant 1 (KLF6-SV1) expression is associated with poor prognosis in prostate, lung and ovarian cancer. 52 By contrast, the mRNA expression level of Krüppel-like factor 6 splice variant 2 (KLF6-SV2) in colorectal cancer tissues was decreased than in corresponding normal tissues. 53 KLF6 expression is also decreased in gastric cancers. It has been implicated that the difference of KLF3 expression is owing to the loss of heterozygosity, mutations and alternative splicing. 54, 55 Identically, the difference in expressional changes exists among various types of cancers. For instance, in our study, KLF3 expression was elevated in lung cancer tissues, and abnormal high level of KLF3 was associated with poor overall survival in patients with lung cancer, which was consistent with previous finding. 56 The decrease in KLF3 reduced cell proliferation, migration and invasion in vitro, and also inhibited tumour growth in BALB/c nude mice, suggesting that KLF3 may function as an oncogene during F I G U R E 8 miR-326 and KLF3 are associated with overall survival (OS) in patients with lung cancer. A, KaplanMeier plots of OS in patients with lung cancer, stratified by miR-326 expression.
The P value was calculated by a logrank test. B, Kaplan-Meier plots of OS stratified by KLF3 expression. The results showed that high levels of KLF3 were associated with significantly poorer OS in patients with lung cancer, P = 0.001 Sp1 is an ubiquitously expressed transcription factor and is considered to be a general transcription factor required for transcription of a large number of housekeeping genes. 40, 62 However, accumulating evidence indicates that Sp1 is upregulated in various types of human cancer, including lung cancer. 63 Consistent with these reports, our study also revealed that Sp1 was increased in lung cancer tissues compared with that in adjacent normal tissues. cancer cell migration by targeting Sp1. 65 Wang et al also revealed that miR-375 could bind to the 3′UTR of Sp1. In lung cancer, Sp1
could be repressed by miR-29c, miR-27b, miR-335 and miR-429 in translational level. [66] [67] [68] Similar to these findings, our previous study revealed that miR-326 was deterred in lung cancer cells, In summary, our study provides evidence that miR-326/Sp1/ KLF3 regulatory axis involves in lung cancer cell proliferation, migration and invasion, which provide leads for the further therapy to patients with lung cancer.
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